期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 77, 期 5, 页码 893-901出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2017.05.050
关键词
cancer risk; CDKN2A; familial melanoma; multiple primary melanoma; mutation testing; survival
类别
资金
- Swedish Cancer Society [CAN 2013/637, CAN 2014/851]
- Radiumhemmet research fund [144073]
- regional and hospital funds in Lund and Stockholm
Background: Worse outcomes have been noted in patients with multiple primary melanomas (MPMs) than in patients with single primary melanomas. Objective: We investigated how family history of melanoma and germline CDKN2A mutation status of MPM patients affects risks of developing subsequent melanomas and other cancers and survival outcomes. Methods: Comprehensive data on cancer diagnoses and deaths of MPM patients, their first-degree relatives, and matched controls were obtained through Swedish national health care and population registries. Results: Familial MPM cases with germline CDKN2A mutations were youngest at the diagnosis of their second melanoma (median age 42 years) and had among the MPM cohorts the highest relative risks (RR) compared to controls of developing >2 melanomas (RR 238.4, 95% CI 74.8-759.9). CDKN2A mutated MPM cases and their first-degree relatives were the only cohorts with increased risks of nonskin cancers compared to controls (RR 3.6, 95% CI 1.9-147.1 and RR 3.2, 95% CI 1.9-5.6, respectively). In addition, CDKN2A mutated MPM cases had worse survival compared with both cases with familial (HR 3.0, 95% CI 1.3-8.1) and sporadic wild-type MPM (HR 2.63, 95% CI 1.3-5.4). Limitations: Our study examined outcomes in subgroups of MPM patients, which affected the sample size of the study groups. Conclusion: This study demonstrates that CDKN2A mutation status and family history ofmelanoma significantly affects outcomes of MPM patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据